

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10144	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT03375307
10146	Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer	ETCTN-wide	No	Breast	https://clinicaltrials.gov/ct2/show/NCT03606967
10204	Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT03816345
10214	Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers	ETCTN-wide	No	Skin and other melanoma	https://clinicaltrials.gov/ct2/show/NCT03816332
10273	A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/ct2/show/NCT03983824
10276	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies	ETCTN-wide (in PII)	Yes	Gastrointestinal, Solid tumors (dose escalation)	https://clinicaltrials.gov/ct2/show/NCT04068194

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10285	Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy	ETCTN-wide	No	Skin and other melanoma	https://clinicaltrials.gov/ct2/show/NCT04557956?id=10285
10292	DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT03907475
10299	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients	ETCTN-wide	No	Lymphoma, Solid tumors (no specified mutations)	https://clinicaltrials.gov/study/NCT06223542
10301	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)	ETCTN-wide	Yes	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04071236
10335	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)	ETCTN-wide	No	Leukemia, Lymphoma	https://clinicaltrials.gov/ct2/show/NCT04301076
10355	A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies	ETCTN-wide	No	Solid tumors (mutations), solid tumor (dose escalation), gynecologic	https://clinicaltrials.gov/ct2/show/NCT04585958

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10358	Phase 1/1B study of DS8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial)	ETCTN-wide	No	Gastrointestinal, Solid tumors (dose escalation), Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04704661
10366	A Phase 1/Randomized Phase 2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT04172532
10371	A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response	ETCTN-wide	No	Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04550494
10401	A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma	ETCTN-wide	No	Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04494113
10422	Abemaciclib and Olaparib for Recurrent Ovarian Cancer	ETCTN-wide	No	Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04633239?id=10422
10433	Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors	ETCTN-wide	No	Solid tumors (no specified mutations), Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04840589
10440	A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis	ETCTN-wide	No	Myeloma	https://clinicaltrials.gov/ct2/show/NCT04847453

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10445	Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer	ETCTN-wide	No	Lung	https://clinicaltrials.gov/study/NCT05353439
10466	A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04981509
10483	Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04963153
10499	Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas	ETCTN-wide	No	Lymphoma, Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05053971
10507	A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma	ETCTN-wide	No	Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05019716
10490	Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05142241
10492	Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer	ETCTN-wide	Yes	Head and neck	https://clinicaltrials.gov/ct2/show/NCT05172245

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10486	Phase 2 Trial of the Combination of the BET Inhibitor, ZEN-3694, and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (CombET)	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05327010
10495	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05372614
10504	A Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)	ETCTN-wide	No	Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05333458
10508	A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL)	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/ct2/show/NCT05272384
10449	A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer	Limited (for dose escalation)	No	Breast	https://clinicaltrials.gov/ct2/show/NCT05111561
10509	A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors	ETCTN-wide	No	ST escalation, Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05372640
10512	A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer	ETCTN-wide	Yes	Lung	https://clinicaltrials.gov/ct2/show/NCT05198830

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ ETCTN- wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10237	A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents	Limited	No	Leukemia	https://clinicaltrials.gov/ct2/show/NCT03816319
10464	A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer	ETCTN- wide	No	Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT05411094
10525	A Phase 1b Trial of ZEN-3694 with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer	ETCTN- wide	No	Breast	https://clinicaltrials.gov/ct2/show/NCT05422794
10487	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation	ETCTN- wide	No	Genitourinary, Endocrine	https://clinicaltrials.gov/ct2/show/NCT05691465
10500	Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma	ETCTN- wide	No	Lymphoma	https://clinicaltrials.gov/ct2/show/NCT05627245
10528	Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors	ETCTN- wide	No	ST Mutations	https://clinicaltrials.gov/ct2/show/NCT05687110
10479	A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors	ETCTN- wide	No	Endocrine, Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT05687123

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ ETCTN- wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10505	A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma	ETCTN-wide	No	Brain	https://clinicaltrials.gov/ct2/show/NCT05432804
10527	A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774	ETCTN-wide	No	ST Mutations	https://clinicaltrials.gov/ct2/show/NCT05687136
10522	A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT05685602
10538	Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/ct2/show/NCT05600894
10546	Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer	ETCTN-wide	No	Breast	https://clinicaltrials.gov/ct2/show/NCT05673200
10553	A Phase II Clinical and Biomarker Study of Darolutamide in Combination with Androgen Deprivation Therapy (ADT) for Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Patients	ETCTN-wide	No	Head and Neck	https://clinicaltrials.gov/ct2/show/NCT05669664

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ ETCTN- wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10558	A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetium 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors	ETCTN-wide	No	Endocrine	https://clinicaltrials.gov/ct2/show/NCT05724108
10563	A phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (Doxil®) in patients with metastatic leiomyosarcoma and other soft tissue sarcomas	ETCTN-wide	No	Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05711615
10597	A Phase 1 trial of APG-1252 (pelcitoclast) and cobimetinib in recurrent ovarian and endometrial cancers	ETCTN-wide	No	Gynecologic	https://clinicaltrials.gov/ct2/show/NCT05691504
10577	Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors	Limited	No	Solid tumor (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05691517
10572	A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774	Limited	No	ST Mutations	https://clinicaltrials.gov/ct2/show/NCT05691491
10590	A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/ct2/show/NCT05886036
10596	A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/ct2/show/NCT05886049

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10579	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors	Limited	No	Solid tumors (dose escalation), GI	https://clinicaltrials.gov/ct2/show/NCT05803382
10601	A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/study/NCT06015880
10559	A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with FGFR-TACC Gene Fusion	ETCTN-wide	No	Brain	https://clinicaltrials.gov/ct2/show/NCT05859334
10592	A Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma	ETCTN-wide	No	Skin and other melanoma	https://clinicaltrials.gov/study/NCT05947500
10614	A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers	ETCTN-wide	No	Skim and other melanoma	https://clinicaltrials.gov/ct2/show/NCT05896839
10605	Phase I Trial of ZEN-3694 in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06102902
10608	A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06050252

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10612	A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma	ETCTN-wide	No	Myeloma	https://clinicaltrials.gov/study/NCT06169215
10629	A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer	ETCTN-wide	No	Lung	https://clinicaltrials.gov/study/NCT06287775
10653	A phase I study of Lintuzumab-Ac-225 in combination with venetoclax and ASTX-727 in adults with newly diagnosed AML	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/study/NCT06802523
10637	Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia	Limited	No	Leukemia	https://clinicaltrials.gov/study/NCT06311227
10554	Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression	Limited for escalation ; wide for expansion	No	Gastrointestinal; Solid tumors (dose escalation)	https://clinicaltrials.gov/study/NCT06364410
10630	Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naïve AML	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/study/NCT06514261

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10636	Phase 1 Trial of CA-4948 in Combination with Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/study/NCT06439836
10657	Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients with Retinoblastoma (Rb)+ Sarcomas	Limited	No	Sarcoma	https://clinicaltrials.gov/study/NCT06498648
10674	A phase I study evaluating the safety of Cirtuvivint as monotherapy and in combination with ASTX727 and ASTX727 + venetoclax in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)	Limited	No	Leukemia	https://clinicaltrials.gov/study/NCT06484062
10620	A Phase 1b Trial of Teclistamab in Combination with Iberdomide for Relapsed/Refractory Multiple Myeloma	ETCTN-wide	No	Myeloma	https://clinicaltrials.gov/study/NCT06465316
10655	Phase I Clinical Trial of CA-4948 in Combination with FOLFOX Plus Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06696768
10675	A Randomized Phase II Trial of ASTX727 +/- ladademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/study/NCT06661915

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10664	Phase 1b Study of Combination Tovorafenib and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib and Rituximab with Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia	ETCTN-wide	No	Leukemia, Lymphoma	https://clinicaltrials.gov/study/NCT06965114
10667	Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors	ETCTN-limited	No	Solid tumor (no specified mutations)	https://clinicaltrials.gov/study/NCT06606990
10670	Phase 1 study of 5-fluorouracil in combination with abemaciclib in metastatic, refractory CRC	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06654037
10660	Histologically or cytologically documented locally advanced or metastatic KRASG12C-mutant non-small cell lung cancer (NSCLC) that has previously been treated with a KRASG12C inhibitor AND an immune checkpoint inhibitor (ICI) and/or chemotherapy, either given concurrently or sequentially.	ETCTN-wide	No	Lung	https://clinicaltrials.gov/study/NCT07012031
10699	A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma	ETCTN-wide	No	Brain	https://clinicaltrials.gov/study/NCT06860594
10666	A Dose-Finding Phase I Study of Bone-targeted Stannic-117m Pentatate (Sn-117m-DTPA) in Solid Tumors with Skeletal Metastases	ETCTN-wide	No	Solid Tumors, NOS	https://clinicaltrials.gov/study/NCT06982222

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10703	A Phase I/II Trial of Sapanisertib in Combination with Cabozantinib in β -Catenin-Mutated Hepatocellular Carcinoma	Limited for escalation ; wide for Phase II	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06811116
10707	Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06730100
10695	Lintuzumab-Ac225 monotherapy for patients with hypomethylating agent-refractory myelodysplastic syndrome	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/study/NCT06888323
10702	A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated with CD19-Directed CAR T-Cell Therapy	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/study/NCT07003295
10706	A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery	ETCTN-wide	No	Head and Neck	https://clinicaltrials.gov/study/NCT06980038
10708	A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/study/NCT07061951
10713	A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma	Limited	No	Brain	Not available currently.
10717	Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/study/NCT07069699

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10727	Phase 1b study of teclistamab in relapsed/refractory plasmablastic lymphoma	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/study/NCT07156227
10716	A Phase 1 and Randomized Phase 2 Trial of CX-5461 (Pidnarulex) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT07147231
10720	Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients with HER2 Expressing Solid Tumors	ETCTN-wide	No	Breast, Solid tumors (mutations)	https://clinicaltrials.gov/study/NCT07137416
10721	Phase II Trial of Neoadjuvant Chemoimmunotherapy vs Chemotherapy in Sinonasal Squamous Cell Carcinoma	Limited	No	Head and Neck	Not available currently.
10732	Phase I trial of ATR inhibitor camonsertib combined with stereotactic body radiation therapy for recurrent head and neck squamous cell carcinoma	Limited	Yes	Head and Neck, Radiation	https://clinicaltrials.gov/study/NCT07156227
10731	Phase 2 Trial of IMC-F106C (Brenetafusp) in Unresectable, Recurrent or Metastatic Adenoid Cystic Cancer	Wide	No	Head and Neck	Not available currently.
10733	Phase I study of the MEK inhibitor Selumetinib plus DS-8201a in KRAS-mutant, HER2-expressing pancreatic ductal adenocarcinoma	Wide	No	Gastrointestinal	Not available currently.
10743	Pilot trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)	Wide	No	Genitourinary	Not available currently.

All ETCTN Trials: Updated September 8, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ ETCTN- wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
<i>10760</i>	A Phase I Study of Glofitamab with Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma	Wide	No	Lymphoma	Not available currently.
<i>10740</i>	A Phase 2 Trial of IMC-F106C, a PRAME Targeted ImmTAC, for Synovial Sarcoma and Myxoid Liposarcoma	Wide	No	Sarcoma	Not available currently.